Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)

被引：19

作者：

Poon, S. ^{[1
]}

Birkett, N. R. ^{[1
]}

Fowler, S. B. ^{[2
]}

Luisi, B. F. ^{[3
]}

Dobson, C. M. ^{[1
]}

Zurdo, J. ^{[2
]}

机构：

[1] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England

[2] Zyentia Ltd, Cambridge CB22 3AT, England

[3] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England

来源：

PROTEIN AND PEPTIDE LETTERS | 2009年 / 16卷 / 12期

关键词：

hGLP-1; protein aggregation; biopharmaceuticals; diabetes; amyloid fibrils; Alzheimer's disease; AMYLOID FIBRIL FORMATION; X-RAY-DIFFRACTION; NEURONAL DEGENERATION; THERAPEUTIC PEPTIDE; DIABETES-MELLITUS; GLOBULAR PROTEIN; SELF-ASSOCIATION; HUMAN CALCITONIN; HUMAN-DISEASE; SH3; DOMAIN;

D O I：

10.2174/092986609789839232

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.

引用

页码：1548 / 1556

页数：9

共 50 条

[1] Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor
Teng, Min
Johnson, Michael D.
Thomas, Christine
Kiel, Dan
Lakis, James N.
Kercher, Tim
Aytes, Shelley
Kostrowicki, Jarek
Bhumralkar, Dilip
Truesdale, Larry
May, John
Sidelman, Ulla
Kodra, Janos T.
Jorgensen, Anker Steen
Olesen, Preben Houlberg
de Jong, Johannes Cornelis
Madsen, Peter
Behrens, Carsten
Pettersson, Ingrid
Knudsen, Lotte Bjerre
Holst, Jens J.
Lau, Jesper
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (19) : 5472 - 5478
[2] Glucagon and glucagon-like peptide-1
Livingston, JN
Schoen, WR
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 189 - 198
[3] Glucagon-like peptide-1
Doyle, ME
Egan, JM
RECENT PROGRESS IN HORMONE RESEARCH, VOL 56, 2001, 56 : 377 - 399
[4] Glucagon-like peptide-1 and glucagon-like peptide-2
Baggio, LL
Drucker, DJ
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 18 (04) : 531 - 554
[5] Bioactivity of a modified human Glucagon-like peptide-1
Xu, Fangfang
Wang, Kevin Yueju
Wang, Nan
Li, Gangqiang
Liu, Dehu
PLOS ONE, 2017, 12 (02):
[6] Glucagon-like peptide-1 and satiety
S. R. Bloom
Nature, 1997, 385 : 214 - 214
[7] Glucagon-Like Peptide-1 and Diabetes
Monami, Matteo
EXPERIMENTAL DIABETES RESEARCH, 2011,
[8] Glucagon-like peptide-1 and satiety
G. van Dijk
T. E. Thiele
R. J. Seeley
S. C. Woods
I. L. Bernstein
Nature, 1997, 385 : 214 - 214
[9] Glucagon-like peptide-1 and satiety
van, Dijk, G.
Thiele, T.E.
Seeley, R.J.
Woods, S.C.
Bernstein, I.L.
Bloom, S.R.
Nature, 1997, 385 (6613)
[10] Glucagon-like peptide-1 receptor
Krashes, Michael
CURRENT BIOLOGY, 2024, 34 (23) : R1163 - R1164

← 1 2 3 4 5 →